Novo Nordisk A/S (NYSE:NVO)
| 91.72 Delayed Data As of Sep 27 |  -0.07 / -0.08%Today’s Change | 47.63 Today|||52-Week Range 100.88 | +35.54% Year-to-Date |
Latest NVO News | Press Releases
Today’s Trading
| Previous close | 91.79 |
| Today’s open | 91.26 |
| Day’s range | 90.61 - 91.86 |
| Volume | 2,945,970 |
| Average volume (3 months) | 3,362,428 |
| Market cap | $620.5B |
Data as of 4:00pm ET, 09/27/2023
Growth & Valuation
| Earnings growth (last year) | +4.77% |
| Earnings growth (this year) | +46.28% |
| Earnings growth (next 5 years) | +18.40% |
| Revenue growth (last year) | +11.71% |
| P/E ratio | 43.7 |
| Price/Sales | 12.30 |
| Price/Book | 60.37 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | -0.27 | -0.05% |
| JNJJohnson & Johnson | -1.91 | -1.20% |
| NONOFNovo Nordisk | -0.97 | -1.05% |
| ABBVAbbVie | -0.78 | -0.51% |
Data as of 4:00pm ET, 09/27/2023
Financials
| Next reporting date | November 2, 2023 |
| EPS forecast (this quarter) | $1.37 |
| Annual revenue (last year) | $25.0B |
| Annual profit (last year) | $7.8B |
| Net profit margin | 31.38% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
